Pneumotox Online
v2.2
  • RSS Feed
  • Contact
  • News
  • Diagnosing DIRD
  • Browse
  • Available on AppStore Available on AppStore

The Drug-Induced Respiratory Disease Website

Philippe Camus, M.D.

Dijon, France

  • Home
  • Browse by »
  • Drugs
  • Patterns

Alemtuzumab

1

XVII.b Opportunistic pulmonary/systemic infections

1
Last update : 31/12/2013
 
Search
Advanced search
Identify causative drugs
Diagnosing DIRD
1
Drug and radiation history
2
Drug singularity - Correct identification of the drug
3
Consistent timing of exposure v. onset of symptoms
4
Clinical, imaging, BAL, pathological pattern consistent with the specific drug
5
Careful exlusion of another cause
6
Remission of symptoms with removal of drug
7
Recurrence with rechallenge (rarely advisable)
8
Causality assessment
More detailed checklist

Publications

Risk of opportunistic infections in patients treated with alemtuzumab for multiple sclerosis.
Expert opinion on drug safety 2018 Jul;17;709-717 2018 Jul
Monoclonal antibody therapy for B-cell non-Hodgkin's lymphoma.
The New England journal of medicine 2008 Aug 07;359;613-26 2008 Aug 07
Rhodococcus equi infection after alemtuzumab therapy for T-cell prolymphocytic leukemia.
Emerging infectious diseases 2007 Dec;13;1942-3 2007 Dec
Efficacy and tolerability of alemtuzumab (CAMPATH-1H) in the salvage treatment of B-cell chronic lymphocytic leukemia--change of regimen needed?
Leukemia & lymphoma 2004 Feb;45;345-9 2004 Feb
Infectious toxicity using alemtuzumab.
Haematologica 2004 Dec;89;1415-9 2004 Dec

Powered by

  • ^
  • Contact
  • Cookies
  • About